Skip to main content

Day: April 8, 2020

EU And Business Finland Have Awarded SSH.COM Further Funding for PrivX® Development

Helsinki, Finland – April 08, 2020 – SSH.COM has been awarded roughly €750,000 in grant-based funding by the European Union and Business Finland for further development of the PrivX product. The funding is a part of the European ECSEL Joint Undertaking established in 2014.SSH.COM estimates that the funding will commence during Q3/2020 after customary preparations are concluded and the agreements are signed. The funding helps take PrivX development further and supports, in particular, the development of machine-to-machine, automation, and IIoT (Industrial Internet of Things) features of PrivX.The funding will be accounted for as a reduction in capitalized product development costs and recognized by way of reduced depreciations. A portion of the funding will be recognized under other operating income from 2020 to 2022 in proportion with...

Continue reading

Euroopan unioni ja Business Finland ovat myöntäneet tuotekehitysrahoitusta SSH.COM:ille PrivX®:n jatkokehitykseen

Helsinki – 8.4.2020 – Euroopan Unioni ja Business Finland ovat myöntäneet SSH.COM:ille noin €750,000 euroa tuotekehitysavustusta PrivX-tuotteen jatkokehitystä varten. Rahoitus on osa vuonna 2014 käynnistettyä EU:n ECSEL Joint Undertaking -ohjelmaa.SSH.COM arvioi rahoituskauden alkavan kuluvan vuoden kolmannen vuosineljänneksen aikana, kun normaalit prosessiin liittyvät valmistelut on saatu päätökseen ja rahoitukseen liittyvät sopimukset on allekirjoitettu. Rahoitus tehostaa PrivX:n jatkokehitystä ja tukee erityisesti m2m-toimintojen, automaation ja IioT-toimintojen (teollinen esineiden internet) kehittämistä.Saatu rahoitus kirjataan aktivoitujen tuotekehitysmenojen vähennykseksi, josta se tuloutuu pienempien poistojen muodossa. Osa rahoituksesta kirjataan muihin liiketoiminnan tuottoihin syntyneiden kulujen suhteessa vuosina 2020-2022.Rahoitus...

Continue reading

Steve Hamil to Join Ebix as Global Chief Financial Officer

JOHNS CREEK, Ga., April 08, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, e-governance and healthcare industries, today announces an addition to its leadership team with the appointment of Steven M. Hamil (Steve) as Executive Vice President and Global Chief Financial Officer. Steve joins Ebix from Regions Financial Corporation where he began in 2013 as Senior Vice President and Managing Director covering the technology, media and communication and defense and government services sectors. Steve has extensive experience in banking and capital markets with NationsBanc Capital Markets (now Bank of America) and Wachovia Capital Markets (Wells Fargo).Through his career, Steve has held senior financial and accounting leadership...

Continue reading

Athabasca Minerals Announces AMI RockChain Completion of $1 Million Order and Corporate Update

CALGARY, Alberta, April 08, 2020 (GLOBE NEWSWIRE) — Athabasca Minerals Inc. (“AMI” or the “Corporation”) – TSXV:AMI – is pleased to announce:AMI RockChain’s recent achievement in completing a $1 million job order for the supply of specialized aggregates product (rail ballast) to a major customer with industrial operations in Central Alberta for a new transload facility.Corporate updates and progress regarding AMI Silica, AMI Aggregates (base division), as well as fiscal management in the face of COVID-19.The appointment of J. Robert Logan, MBA, ICD.D as Advisor to AMI’s Board of Directors with regard to the Corporation’s strategic business interests in 2020 and capital markets.Robert Beekhuizen, Chief Executive Officer, states: “Although we commonly face very challenging times right now, given the COVID-19 situation, AMI is adapting...

Continue reading

Även europeiska läkemedelsmyndigheten positiv till Corlines planerade fas 2-studie

Den 11 mars 2020 var Corline inbjudet till rådgivningsmöte (Protocol Assistance) med den europeiska läkemedelsmyndigheten EMA för att diskutera bolagets planerade fas 2-studie för Renaparin®. Bolaget har nu erhållit EMA:s officiella mötesanteckningar där viktiga slutsatser är att EMA accepterar Corlines nuvarande prekliniska data och den pågående fas 1-studien – RENAPAIR 01 – som grund för fortsatt klinisk utveckling och marknadslansering, utan krav på kompletteringar. Råden från EMA linjerar med de som tidigare erhållits från FDA, vilket innebär att en gemensam fas 2-studie kan genomföras. Detta innebär en snabbare och mer kostnadseffektiv utvecklingsplan.Protocol Assistance-möte begärs av bolag och EMA håller sådana möten för att förbereda kliniska studier och efterföljande marknadsgodkännande i EU för nya läkemedel under utveckling....

Continue reading

NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 08, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary...

Continue reading

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.“Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter,” said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics.  “Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers. As an organization we have taken...

Continue reading

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 08, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Needham Virtual Healthcare Conference on April 15, 2020 at 12:00 p.m. ET.A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing...

Continue reading

Recordati Rare Diseases now holds Isturisa® European MA

Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome  Paris, 8 April, 2020 – Recordati Rare Diseases today announces the transfer of the European Marketing Authorization of Isturisa® (osilodrostat). The transfer includes all EU member states plus the UK, Norway, Iceland and Liechtenstein.Isturisa® is authorized for the treatment of adult patients with Cushing’s syndrome. Isturisa® is a potent inhibitor of 11β-­hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis1. Isturisa® has demonstrated rapid and sustained normalization of cortisol levels in a significant proportion of adult patients with a manageable safety profile, making this a novel oral treatment option for patients with Cushing’s...

Continue reading

Intertape Polymer Group: COVID-19 Update

MONTREAL and SARASOTA, Fla., April 08, 2020 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG” or the “Company”) today provided an update on its operations during the coronavirus COVID-19 (“COVID-19”) pandemic. The Company’s North American and European manufacturing operations are open and producing as a result of the essential nature of the end markets it serves.“Safety is our highest priority. As such, we are committed to ensuring a safe work environment for our employees, as well as their safety once they return home to their family,” said Greg Yull, President and CEO of IPG. “Our employees at the manufacturing facilities are performing work that is critical to the integrity of the supply chain for our end users that provide essential goods and services. The layout of our manufacturing lines allows for social distancing,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.